Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10167796 | 1.00 | MMP13 (0.46) | MMP13MMP1MMP9NAMPTGPR119 | |
| SCHEMBL567178 | 0.94 | NAMPT (0.45) | MMP13MMP1MMP9NAMPTGPR119 | |
| SCHEMBL567177 | 0.94 | NAMPT (0.45) | MMP13MMP1MMP9NAMPTGPR119 | |
| SCHEMBL567260 | 0.93 | MMP1 (0.43) | MMP13MMP1MMP9NAMPTGPR119 | |
| SCHEMBL567261 | 0.93 | MMP1 (0.43) | MMP13MMP1MMP9NAMPTGPR119 | |
| SCHEMBL567576 | 0.92 | MMP13 (0.51) | MMP13MMP1MMP9GPR119ADAM17 | |
| SCHEMBL567993 | 0.92 | MMP13 (0.51) | MMP13MMP1MMP9GPR119ADAM17 | |
| SCHEMBL567577 | 0.92 | MMP13 (0.51) | MMP13MMP1MMP9GPR119ADAM17 | |
| SCHEMBL567645 | 0.90 | MMP1 (0.49) | MMP13MMP1MMP9GPR119ADAM17 | |
| SCHEMBL567685 | 0.90 | MMP1 (0.49) | MMP13MMP1MMP9GPR119ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-2444395-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2010146881-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | 株式会社デ・ウエスタン・セラピテクス研究所 (JP) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | MMP13 4729/4885MMP1 4000/4885MMP9 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.